TEVA PHARMACEUTICALS USA

DC

Pharmaceutical company

Active 2007–2026. The register lists this client once for every firm that files on its behalf; all 15 of its records are shown together here.

Filings
358
Filed By
15
Reported In-House
$62,600,000
Reported By Firms
$12,325,000

These two figures are not added together. A client that lobbies for itself reports its own spending, while firms it retains report what they were paid. Disclosure rules ask the in-house figure to include those payments, but filings do not always do so, and a filing gives no way to tell. Each is shown as reported.

Filings

YearFirmPeriodAmountDoc
2026 CAPITOL HILL CONSULTING GROUP 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$20,000
2026 TEVA PHARMACEUTICALS USA, INC. 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$310,000
2026 CAPITOL HILL CONSULTING GROUP 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$60,000
2026 TEVA PHARMACEUTICALS USA, INC. 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$380,000
2026 CAPITOL HILL CONSULTING GROUP 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
$60,000
2026 TEVA PHARMACEUTICALS USA, INC. 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
$1,100,000
2025 CAPITOL HILL CONSULTING GROUP 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
$60,000
2025 TEVA PHARMACEUTICALS USA, INC. 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
$360,000
2025 CAPITOL HILL CONSULTING GROUP 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$60,000
2025 TEVA PHARMACEUTICALS USA, INC. 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$460,000
Page 1 of 36  ·  358 filings Next
Filed By
Issue Areas

Bills Mentioned in Filings